These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6420716)

  • 1. DDAVP in uremia.
    Vicente V; Alberca I; Macias JF; Lopez Borrasca A
    Nephron; 1984; 36(2):145-6. PubMed ID: 6420716
    [No Abstract]   [Full Text] [Related]  

  • 2. 1-Deamino-8-D-arginine vasopressin lowers protein C activity in uremics.
    Aunsholt NA; Schmidt EB; Stoffersen E
    Nephron; 1989; 53(1):6-8. PubMed ID: 2506477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) infusion in normal subjects.
    Takahashi H; Itoh M; Kobayashi I; Sakuragawa N; Shibata A
    Tohoku J Exp Med; 1980 Oct; 132(2):133-40. PubMed ID: 6777902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DDAVP, cryoprecipitate, and highly 'purified' factor VIII concentrate in uremia.
    Juhl A
    Nephron; 1986; 43(4):305-6. PubMed ID: 3090461
    [No Abstract]   [Full Text] [Related]  

  • 5. Is the pro-adhesive activity of plasma von Willebrand factor counteracted by a physiological inhibitor of platelet adhesiveness?
    Porta M; Cagliero E; Kohner EM
    Clin Sci (Lond); 1982 Feb; 62(2):239-42. PubMed ID: 6797774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New ways to boost factor VIII in hemophilia: DDAVP for mild hemophilia A, von Willebrand's.
    Marwick C
    JAMA; 1983 Jun; 249(24):3278-9. PubMed ID: 6406692
    [No Abstract]   [Full Text] [Related]  

  • 7. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia.
    Mannucci PM; Remuzzi G; Pusineri F; Lombardi R; Valsecchi C; Mecca G; Zimmerman TS
    N Engl J Med; 1983 Jan; 308(1):8-12. PubMed ID: 6401193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced effect of exercise and DDAVP on factor VIII-von Willebrand Factor and plasminogen activator after sequential application of both the stimuli.
    Vicente V; Alberca I; Mannucci PM
    Thromb Haemost; 1984 Feb; 51(1):129-30. PubMed ID: 6426078
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of desmopressin (DDAVP) in the preparation of improved factor VIII concentrate.
    Mikaelsson M; Nilsson IM; Cedergren B; Jonsson S; Rydberg L; Wiechel B
    Scand J Haematol Suppl; 1984; 40():93-101. PubMed ID: 6433478
    [No Abstract]   [Full Text] [Related]  

  • 10. [Studies on the properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) in normal individuals (author's transl)].
    Takahashi H; Itoh M; Kobayashi I; Hattori A; Takahashi K; Sakuragawa N; Shibata A; Tsukada T
    Nihon Ketsueki Gakkai Zasshi; 1980 Oct; 43(5):907-17. PubMed ID: 6785953
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of DDAVP on plasma level of factor XII.
    Nenci GG; Berrettini M; De Cunto M; Agnelli G
    Br J Haematol; 1983 Jul; 54(3):489-92. PubMed ID: 6407513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absent factor VIII response to synthetic vasopressin analogue (DDAVP) in nephrogenic diabetes insipidus.
    Kobrinsky NL; Doyle JJ; Israels ED; Winter JS; Cheang MS; Walker RD; Bishop AJ
    Lancet; 1985 Jun; 1(8441):1293-4. PubMed ID: 2860491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease.
    Holmberg L; Nilsson IM; Borge L; Gunnarsson M; Sjörin E
    N Engl J Med; 1983 Oct; 309(14):816-21. PubMed ID: 6412139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor VIII-related activities after 1-deamino-8-D-arginine vasopressin in multicentric reticulohistiocytosis.
    Taddeo U; Trotta F; Menegale G; Ballerini G
    Ric Clin Lab; 1984; 14(1):37-9. PubMed ID: 6427880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Availability of endothelial von Willebrand factor and platelet function in diabetic patients infused with a vasopressin analogue.
    Porta M
    Diabetologia; 1982 Nov; 23(5):452-5. PubMed ID: 6816652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of 1-deamino-8-D-arginine vasopressin (DDAVP) on bleeding time in uremic patients].
    Alarcón F; Mezzano D; Vial S; Pereira J
    Rev Med Chil; 1985 Aug; 113(8):763-8. PubMed ID: 3938558
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities.
    Moffat EH; Giddings JC; Bloom AL
    Br J Haematol; 1984 Aug; 57(4):651-62. PubMed ID: 6430337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of 1-deamino-8-D-arginine vasopressin (DDAVP) on blood coagulation in patients with hemophilia A and in healthy men].
    Blättler W; Jacky E; Müller M; Graf M
    Schweiz Med Wochenschr; 1979 Sep; 109(37):1367-8. PubMed ID: 314661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High levels of circulating von Willebrand factor inhibit the release of this protein but not of plasminogen activator after DDAVP.
    Vicente V; Alberca I; Mannucci PM
    Thromb Res; 1985 Apr; 38(1):101-5. PubMed ID: 3873723
    [No Abstract]   [Full Text] [Related]  

  • 20. [Response to DDAVP in von Willebrand disease type II C].
    Batllé Fonrodona J; López Fernández MF; Martín González R; Fernández Villamor A; López Borrasca A; Lasierra Cirujeda J
    Sangre (Barc); 1985; 30(2):181-4. PubMed ID: 3925573
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.